ReviewNutrients2023
Advances in Research on Marine-Derived Lipid-Lowering Active Substances and Their Molecular Mechanisms.
Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Herbal Interventions in Parkinson's Disease: A Systematic Review of Preclinical Studies.Cellular and molecular neurobiology · 2025Pooled it
- Evaluating the Clinical Impact of a Polyphenol-Rich Extract fromNutrients · 2024Trial
- Research Progress on Marine Active Substances in Improving Atherosclerosis.Marine drugs · 2026Review
- Review
- Edible Marine Red AlgaFoods (Basel, Switzerland) · 2026Article
- Lipidomic Characterization of Marine By-Product Oils: Impact of Species and Extraction Methods on Lipid Profile and Antioxidant Potential.Antioxidants (Basel, Switzerland) · 2026Article
- Valorisation of fish scales and bones: a sustainable source of bioactive proteins and collagen for nutraceuticals.Bioresources and bioprocessing · 2025Review
- Exploring the potential ofNarra J · 2025Article
- Lipidomic Characterization of Muscle and Head ofFood science & nutrition · 2025Article
- Marine-Derived Polymers-Polysaccharides as Promising Natural Therapeutics for Atherosclerotic Cardiovascular Disease.Marine drugs · 2025Review
- Bioactive Peptides Derived from Tuna: Screening, Extraction, Bioactivity, and Mechanism of Action.Marine drugs · 2025Review
- Efficient Hydrolysis of Earthworm Protein and the Lipid-Lowering Mechanism of Peptides in the Hydrolysate.Foods (Basel, Switzerland) · 2025Article
- Peptides fromMarine drugs · 2025Article
- Virtual screening and evaluation of bioactive peptides fromFrontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Hyperlipidemia (HLP) is a metabolic disorder caused by abnormal lipid metabolism. Recently, the prevalence of HLP caused by poor dietary habits in the population has been increasing year by year. In addition, lipid-lowering drugs currently in clinical use have shown significant improvement in blood lipid levels, but are accompanied by certain side effects. However, bioactive marine substances have been shown to possess a variety of physiological activities such as hypoglycemic, antioxidant, antithrombotic and effects on blood pressure. Therefore, the hypolipidemic efficacy of marine bioactive substances with complex and diverse structures has also attracted attention. This paper focuses on the therapeutic role of marine-derived polysaccharides, unsaturated fatty acids, and bioactive peptides in HLP, and briefly discusses the main mechanisms by which these substances exert their hypolipidemic activity in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.